jueves, 19 de enero de 2012

NOVARTIS: La renuncia...

"Si mi presencia te incomoda
para poderlo mirar
me voy, me voy de aqui
para que vivas tu romance,
no te preocupes
ya entendi tus indirectas
no hace falta que me mientas
me voy para no estorbarte..."

Dario Gómez/Mi renuncia


Alegría en Nyon después de la renuncia al cierre por Novartis.
Recortes planeados de empleos en Basilea se reduce significativamente.
Ver

Nearly three months of sustained pressure has prompted Novartis to change its corporate mind and abandon plans to close a plant in Vaud, Switzerland, a step that will save about 320 jobs. At the same time, the drugmaker will elminate fewer than the 760 jobs that were originally to have been cut at a chemical plant in Basel.
The move comes in response to demonstrations by Novartis workers, protests from local politicians and, in one case, a publicized boycott of Novartis medicines by a doctor in Switzerland (see here), where the drugmaker is headquartered and residents were unnerved by the extent of the planned job cuts. Until recently, Novartis employees in other countries have borne the brunt of widespread layoffs.
Last week, the drugmaker disclosed plans to axe 1,630 US sales reps and another 360 positions from its US headquarters in New Jersey in response to a failed clinical trial for a hypertension med (read here). Another 900 jobs were trimmed last fall from the US and, in 2010, the drugmaker slashed 1,400 US sales reps and another 550 jobs at a manufacturing site in the UK (back story).
But plans announced last fall to eliminate 1,100 jobs from Switzerland caused an uproar, especially since of the work was to have been outsourced to China and India. Unlike in other countries, though, Novartis has given in to public outcry. Although what apparently helped the drugmaker to reverse course are some temporary tax breaks issued by the local government in Vaud, where an investment will be made to modernize the plant. (Más)

Ver también:

Armin Zust, bombero? Así es la vida...de caprichosa..


NOVARTIS cesa...


Novartis reverses plant closure plans

No hay comentarios: